Various experimental strategies aim to (re)activate p53 signalling in cancer cells. The most advanced clinically are small-molecule inhibitors of the autoregulatory interaction between p53 and MDM2 (murine double minute 2). Different MDM2 inhibitors are currently under investigation in clinical trials. As for other targeted anti-cancer therapy approaches, relatively rapid resistance acquisition may limit the clinical efficacy of MDM2 inhibitors. In particular, MDM2 inhibitors were shown to induce p53 mutations in experimental systems. In the present article, we summarize what is known about MDM2 inhibitors as anti-cancer drugs with a focus on the acquisition of resistance to these compounds.
Conference Article| August 11 2014
Resistance acquisition to MDM2 inhibitors
- Views Icon Views
- Share Icon Share
- Cite Icon Cite
Jindrich Cinatl, Daniel Speidel, Ian Hardcastle, Martin Michaelis; Resistance acquisition to MDM2 inhibitors. Biochem Soc Trans 1 August 2014; 42 (4): 752–757. doi: https://doi.org/10.1042/BST20140035
Download citation file: